Mer­ck KGaA teams up with Ital­ian on­col­o­gy group in PARP1 de­vel­op­ment deal

An Ital­ian group has al­lied it­self with Mer­ck KGaA in an on­col­o­gy li­cens­ing deal, seek­ing to get in on the mar­ket op­por­tu­ni­ty and ex­pand its reach in a pos­si­bly block­buster mar­ket.

Mer­ck KGaA and Ital­ian on­col­o­gy com­pa­ny Ner­viano Med­ical Sci­ences joint­ly an­nounced Wednes­day that they are col­lab­o­rat­ing on a li­cens­ing deal for NMS’s PARP1 in­hibitor. Called NMS-293, the drug can­di­date is cur­rent­ly in clin­i­cal tri­als to treat pa­tients as a monother­a­py with a spe­cif­ic type of tu­mor: BR­CA-mu­tat­ed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER